PDCD1 and acute myeloid leukemia: A phase 2 study showed that the association between the PD1 inhibitor nivolumab and AZA determines an encouraging response rate and overall survival in patients with R/R AML; the greatest results were seen in the subset of patients who had not been previously exposed to hypomethylating agents [45].